Related Experiment Videos
Role of endothelin-1 in myocardial failure
1Boston Medical Center, MA 02118, USA.
Insights
Endothelin-1 (ET-1) plays a key role in cardiovascular regulation. Blocking ET-1 receptors shows promise in treating heart failure by improving hemodynamics and survival.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Pharmacology
Background:
- Endothelin-1 (ET-1) is a potent vasoconstrictor involved in cardiovascular regulation.
- Elevated plasma ET-1 levels are observed in patients with heart failure.
- ET-1 influences vascular smooth muscle and cardiac myocyte structure and function.
Purpose of the Study:
- To investigate the role of Endothelin-1 (ET-1) in the pathophysiology of heart failure.
- To evaluate the therapeutic potential of ET-1 receptor antagonists in heart failure models and early clinical trials.
Main Methods:
- Review of existing literature on ET-1 actions and heart failure.
- Analysis of data from animal models of heart failure treated with ET-1 receptor antagonists.
- Examination of results from early-phase clinical trials of ET receptor blockers.
Main Results:
- Animal studies show short-term hemodynamic benefits and long-term improvements in ventricular remodeling and survival with ET-1 receptor antagonists.
- Early clinical trials demonstrate systemic vasodilation as a result of ET receptor blockade.
Conclusions:
- ET-1 is implicated in the pathophysiology of heart failure.
- ET-1 receptor antagonists represent a potential therapeutic strategy for heart failure.
- Ongoing long-term clinical trials are crucial to confirm efficacy for symptoms and survival.
Abstract:
Endothelin-1 (ET-1) is a potent molecule produced throughout the cardiovascular system; it can exert important effects on both the structure and function of vascular smooth muscle cells and cardiac myocytes. ET-1 appears to play a central role in the physiological regulation of cardiovascular function, particularly in the vasculature. The known actions of ET-1 and the demonstration that plasma ET-1 is elevated in patients with heart failure has raised the possibility that this molecule could play a role in the pathophysiology of heart failure. This thesis has been supported and furthered by studies in animal models of heart failure that demonstrate the salutary, short-term effects of ET-1 receptor antagonists on hemodynamic function, as well as improved ventricular remodeling and survival with long-term administration. Early clinical trials with these ET receptor blockers have demonstrated systemic vasodilation. Long-term trials to determine the effects of ET-1 blockade on symptoms and survival are under way.